Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MMP9 | P14780 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 16/20 | 0.45 |
| ▸ | CA9 | Q16790 | 15/20 | 0.45 |
| ▸ | CA1 | P00915 | 15/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA3 | P07451 | 4/20 | 0.31 |
| ▸ | CA4 | P22748 | 4/20 | 0.31 |
| ▸ | CA6 | P23280 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1142936 | 0.93 | KDM4E (0.65) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL27187302 | 0.91 | TSHR (0.62) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL9253800 | 0.91 | TSHR (0.62) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL21070050 | 0.91 | TSHR (0.62) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL10726607 | 0.91 | TSHR (0.62) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL25344898 | 0.91 | TSHR (0.62) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL15887083 | 0.91 | TSHR (0.62) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL312544 | 0.86 | — | — | |
| SCHEMBL611363 | 0.78 | CA2 (0.47) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL9500520 | 0.77 | TSHR (0.61) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | LES LABORATOIRES SERVIER (FR) | 2026-03-10 | — | — | US | disclosed |
| US-20250354195-A1 | METHOD OF SCREENING | UNIV DUNDEE (GB) | 2025-11-20 | — | — | US | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| EP-4624466-A1 | DEGRADER FOR DECOMPOSING CMET PROTEIN, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Innocure Therapeutics, Inc. (KR) | 2025-10-01 | — | — | EP | disclosed |
| US-20250233206-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY EMPLOYING THE SAME | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-07-17 | — | — | US | disclosed |
| US-12315883-B2 | Non-aqueous electrolyte solution and non-aqueous electrolyte secondary battery employing the same | MITSUBISHI CHEMICAL CORPORATION (JP) | 2025-05-27 | — | — | US | disclosed |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| WO-2024263586-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | PAQ Therapeutics Inc. (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| US-5534483-A | (2-imidazolin-2-yl) fused heteropyridine compounds intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5534485-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1996-07-09 | — | — | US | disclosed |
| US-5532207-A | CONTROL OF MONO- AND DI-COTYLEDONOUS ANNUAL, PERENNIAL AND AQUATIC PLANTS; PRE- AND POST-EMERGENCE USE | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5510319-A | PYRROLO-2,3-B-PYRIDINYL DERIVATIVES | AMERICAN CYANAMID COMPANY (US) | 1996-04-23 | — | — | US | disclosed |
| US-5466710-A | Heterobicycloalkanes as pesticidal compounds | ROUSSEL UCLAF (FR) | 1995-11-14 | — | — | US | disclosed |
| US-5252538-A | (2-imidazolin-2-yl) fused heteropyridine compounds, intermediates for the preparation of and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0227932-B1 | NOVEL FUSED PYRIDINE COMPOUNDS, INTERMEDIATES FOR THE PREPARATION OF, AND USE OF SAID COMPOUNDS AS HERBICIDAL AGENTS | AMERICAN CYANAMID COMPANY (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5116862-A | Acetylenic trithiabicyclo(2.2.2)octanes | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-26 | — | — | US | disclosed |
| EP-0300797-A1 | Pesticidal compounds | ROUSSEL UCLAF (FR) | 1989-01-25 | — | — | EP | disclosed |
| EP-0227932-A1 | Novel fused pyridine compounds, intermediates for the preparation of, and use of said compounds as herbicidal agents | AMERICAN CYANAMID COMPANY (US) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570648-B2 | 6,7-dihydro-5H-pyrido[2,3-c]pyridazine derivatives and related compounds as Bcl-xL protein inhibitors and pro-apoptotic agents for treating cancer | BCOR, BCL2A1, BAK1 | USP2 3829/4885TSHR 2410/4885KDM4E 3289/4885 |
| US-20250354195-A1 | METHOD OF SCREENING | PAICS, COASY, ABCG2 | USP2 705/4885TSHR 3289/4885KDM4E 4166/4885 |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | USP2 2961/4885TSHR 2394/4885KDM4E 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.